EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection
Name
EGLN1 inhibition.pdf
Size
1.93 MB
Format
Adobe PDF
Checksum (MD5)
fa73c50cc01d73425eec2ddf8e2414b7
Author(s)
Olenchock, Benjamin A.
Moslehi, Javid
Baik, Alan H.
Williams, Jeremy
Gibson, William J.
Chakraborty, Abhishek A.
Pierce, Kerry A.
Miller, Christine M.
Hanse, Eric A.
Kelekar, Ameeta
Date Issued
February 2016
Journal
Cell
Publisher
Elsevier
Citation
Olenchock, Benjamin A. et al. “EGLN1 Inhibition and Rerouting of α-Ketoglutarate Suffice for Remote Ischemic Protection.” Cell 164.5 (2016): 884–895.
Version
Author's final manuscript
Abstract
Ischemic preconditioning is the phenomenon whereby brief periods of sublethal ischemia protect against a subsequent, more prolonged, ischemic insult. In remote ischemic preconditioning (RIPC), ischemia to one organ protects others organs at a distance. We created mouse models to ask if inhibition of the alpha-ketoglutarate (αKG)-dependent dioxygenase Egln1, which senses oxygen and regulates the hypoxia-inducible factor (HIF) transcription factor, could suffice to mediate local and remote ischemic preconditioning. Using somatic gene deletion and a pharmacological inhibitor, we found that inhibiting Egln1 systemically or in skeletal muscles protects mice against myocardial ischemia-reperfusion (I/R) injury. Parabiosis experiments confirmed that RIPC in this latter model was mediated by a secreted factor. Egln1 loss causes accumulation of circulating αKG, which drives hepatic production and secretion of kynurenic acid (KYNA) that is necessary and sufficient to mediate cardiac ischemic protection in this setting.
MIT Department
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.cell.2016.02.006
